We recently revealed that the Akt inhibitor triciribine (TCN) can efficiently induce the differentiation of NB4 APL cells and AML M2-derived HL-60 cells through activation of the ERK/MAPK pathway [11]. The gene discussed is AKT1; the disease is acute myeloid leukemia.